These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 25975191)

  • 1. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
    Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
    Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
    de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
    J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
    Nijhof IS; Casneuf T; van Velzen J; van Kessel B; Axel AE; Syed K; Groen RW; van Duin M; Sonneveld P; Minnema MC; Zweegman S; Chiu C; Bloem AC; Mutis T; Lokhorst HM; Sasser AK; van de Donk NW
    Blood; 2016 Aug; 128(7):959-70. PubMed ID: 27307294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
    Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
    Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
    Nijhof IS; Lammerts van Bueren JJ; van Kessel B; Andre P; Morel Y; Lokhorst HM; van de Donk NW; Parren PW; Mutis T
    Haematologica; 2015 Feb; 100(2):263-8. PubMed ID: 25510242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma.
    Mustafa N; Nee AHF; Chooi JY; Toh SHM; Chung TH; Selvarajan V; Fan S; Ng SB; Poon M; Chan E; Lee J; Chee YL; Jeyasekharan AD; Zhou L; Yang J; Chng WJ
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
    Xia C; Ribeiro M; Scott S; Lonial S
    Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
    van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
    Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma.
    Nakamura A; Suzuki S; Kanasugi J; Ejiri M; Hanamura I; Ueda R; Seto M; Takami A
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
    Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
    Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
    [No Abstract]   [Full Text] [Related]  

  • 11. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.
    Naeimi Kararoudi M; Nagai Y; Elmas E; de Souza Fernandes Pereira M; Ali SA; Imus PH; Wethington D; Borrello IM; Lee DA; Ghiaur G
    Blood; 2020 Nov; 136(21):2416-2427. PubMed ID: 32603414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma.
    Lejeune M; Duray E; Peipp M; Clémenceau B; Baron F; Beguin Y; Caers J
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
    Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
    Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease.
    Shrestha P; Astter Y; Davis DA; Zhou T; Yuan CM; Ramaswami R; Wang HW; Lurain K; Yarchoan R
    Oncoimmunology; 2023; 12(1):2163784. PubMed ID: 36632565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
    van de Donk NWCJ; Usmani SZ
    Front Immunol; 2018; 9():2134. PubMed ID: 30294326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma.
    Ise M; Matsubayashi K; Tsujimura H; Kumagai K
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):e59-64. PubMed ID: 26997107
    [No Abstract]   [Full Text] [Related]  

  • 17. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
    Plesner T; van de Donk N; Richardson PG
    Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
    Sanchez L; Wang Y; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
    Krejcik J; Casneuf T; Nijhof IS; Verbist B; Bald J; Plesner T; Syed K; Liu K; van de Donk NW; Weiss BM; Ahmadi T; Lokhorst HM; Mutis T; Sasser AK
    Blood; 2016 Jul; 128(3):384-94. PubMed ID: 27222480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.